Table 1.
Baseline characteristics stratified according to ESVEA
| N | All |
- ESVEA |
+ ESVEA |
P value |
|---|---|---|---|---|
| 782 | 681 | 101 | ||
| Age (years) | 58.6 ± 15.5 | 57.2 ± 15.0 | 68.0 ± 15.5 | <.001 |
| Sex (female) | 442 (56.5%) | 391 (57.4%) | 51 (50.5%) | .19 |
| CHA₂DS₂-VASc | 2 (1, 3) | 2 (1, 3) | 3 (1, 4) | <.001 |
| Hypertension | 347 (44.4%) | 287 (42.1%) | 60 (59.4%) | .001 |
| Ischemic stroke | 54 (6.9%) | 42 (6.2%) | 12 (11.9%) | .035 |
| Diabetes mellitus | 93 (11.9%) | 81 (11.9%) | 12 (11.9%) | .99 |
| Ischemic heart disease | 95 (12.1%) | 73 (10.7%) | 22 (21.8%) | .001 |
| Hypercholesterolemia | 278 (35.5%) | 236 (34.7%) | 42 (41.6%) | .17 |
| INDICATION FOR MONITORING | ||||
| Palpitations | 247 (31.6%) | 215 (31.5%) | 32 (31.6%) | .98 |
| Dizziness, syncope | 387 (49.5%) | 343 (50.4%) | 44 (43.6%) | .20 |
| Efficacy of treatment | 20 (2.6%) | 19 (2.8%) | 1 (1.0%) | .28 |
| Unspecified suspicion of arrhythmia | 128 (16.3%) | 104 (15.3%) | 24 (23.8%) | .031 |
| MEDICATIONS | ||||
| ACE/ARB | 215 (27.5%) | 180 (26.4%) | 35 (34.7%) | .084 |
| Beta-blocker | 163 (20.8%) | 144 (21.1%) | 19 (18.8%) | .59 |
| Diuretics | 171 (21.9%) | 138 (20.3%) | 33 (32.7%) | .005 |
| Calcium channel blocker | 142 (18.2%) | 116 (17.0%) | 26 (25.7%) | .034 |
| Statins | 248 (31.7%) | 205 (30.1%) | 43 (42.6%) | .012 |
| Aspirin | 235 (30.1%) | 204 (30.0%) | 31 (30.7%) | .88 |
| ADP-receptor antagonists | 63 (8.1%) | 50 (7.3%) | 13 (12.9%) | .057 |
| PACs/day | 16 (0.5, 96) | 9.5 (0, 48) | 1423 (690, 3708) | <.001 |
| Longest run of PACs | 0 (0, 6) | 0 (0, 5) | 14 (5, 28) | <.001 |
Values are mean ± SD, n (%), or median (Q1–Q3).
AF = atrial fibrillation; ACE = angiotensin-converting enzyme inhibitor; ARB = angiotensin II receptor blocker; ESVEA = excessive supraventricular ectopic activity; PACs = premature atrial contractions.